27 results about "Interstitial cell" patented technology

The invention relates to the technical field of biological medicine, and discloses rapamycin-loaded microemulsion gel as well as a preparation method and application thereof. The preparation method of the microemulsion gel comprises the following steps: dissolving N, N-dimethyl octadecyl carboxymethyl chitosan in a water phase, then adding an oil phase, a cosurfactant and rapamycin, and stirring to obtain rapamycin-loaded microemulsion; the preparation method comprises the following steps: dissolving a high polymer material in a PBS solution, heating until the high polymer material is completely dissolved, then adding dopamine, stirring for reaction, and finally dialyzing and freeze-drying to obtain the adhesive. And adding a gel matrix containing a thickening agent and an adhesive into the microemulsion, and stirring to obtain the rapamycin-loaded microemulsion gel. According to the prepared microemulsion gel, transdermal drug delivery of hydrophobic drugs is achieved, testis are coated with the microemulsion gel loaded with rapamycin, the blocking effect of damp-heat stress on differentiation and development of testis interstitial cells can be relieved, and the functionality of a male reproduction endocrine system is recovered.

The invention belongs to the technical field of biological medicine research, and particularly relates to a cell in-vitro calcification inducer, an induction culture medium and application thereof, an aortic valve calcification in-vitro induction model and a modeling method thereof. The inducer provided by the invention is prepared from the following components in parts by weight: 2160.4 parts of beta-sodium glycerophosphate, 0.039 parts of dexamethasone, 50 parts of vitamin C and 34 parts of vitamin D. The invention further provides a culture medium formed by using the inducer and a method for modeling an aortic valve calcification in-vitro induction model by using the inducer. According to the method, osteogenic differentiation of the aortic valve interstitial cells can be stably induced within a short time, an efficient and repeatable standardized induction scheme is provided for in-vitro aortic valve calcification models and drug screening, and the method has a very good application prospect.

The invention belongs to the field of biological medicine, and relates to application of triptolide in preparation of a medicine for preventing and treating calcified aortic valve diseases. The triptolide is found to be capable of promoting expression and maturation of CTSD and activating enzyme activity of the CTSD, meanwhile, biogenesis of lysosome in valvular interstitial cells can be promoted by regulating and controlling AKT / mTOR / TFEB signal axes, lysosome functions are improved, autophagy flux is recovered, and finally the effect of treating the calcified aortic valve disease is achieved. A novel treatment medicine is provided for the calcified aortic valve disease.

This invention belongs to the field of biomedical technology and relates to the application of OSM inhibitors in the preparation of drugs for the prevention or treatment of calcific aortic valve disease. This invention reveals for the first time that OSM drives osteogenic differentiation and calcified nodule formation of valvular interstitial cells through the OSM-OSMR-JAK2 / JAK3-STAT3-RUNX2 signaling axis, which is the core pathogenic mechanism leading to calcific aortic valve disease. This invention utilizes anti-OSM neutralizing antibodies or sulforaphane to effectively block this signaling axis, significantly inhibiting macrophage infiltration, valvular calcification, and improving hemodynamic abnormalities. This invention provides a precise target and a novel strategy for the modification therapy of calcific aortic valve disease, solving the technical problem of the ineffectiveness of traditional broad-spectrum anti-inflammatory therapy in valvular calcification.

The invention relates to the technical field of genetic engineering, in particular to application of PCK1 in preparation of products for regulating and controlling goat testicular interstitial cell proliferation. According to the invention, an over-expression plasmid pcDNA3.1 (+)-PCK1 of the PCK1 gene is constructed, an interference sequence si-PCK1 of the PCK1 gene is synthesized, and it is proposed for the first time that the over-expression of the PCK1 gene can significantly promote the proliferation of goat testicular interstitial cells, and the inhibition of the expression of the PCK1 gene can significantly inhibit the proliferation of the goat testicular interstitial cells. The invention has important significance for improving the development of the goat testis, and provides technical support for researching and developing related products for regulating and controlling the proliferation of the goat testis interstitial cells by taking the PCK1 gene as the target spot.

The invention provides application of disulfiram in preparation of a medicine for treating calcified aortic valve diseases, and belongs to the field of biological medicine. The disulfiram is used for intervening in-vitro cultured valvular interstitial cells and a mouse in-vivo calcified aortic valve stenosis model, and experimental results show that the disulfiram can inhibit the capability of differentiating the valvular interstitial cells to osteogenic phenotypes, relieve extracellular calcification deposition and relieve aortic valve calcification and stenosis. Therefore, the disulfiram can be used as a medicine for treating the calcified aortic valve disease and has a wide application prospect.

The invention discloses application of H-151 in preparation of drugs for preventing and treating calcified aortic valve diseases, relates to the technical field of biological medicines, and is characterized in that the invention provides application of an STING inhibitor H-151 or pharmaceutically acceptable salts thereof in preparation of drugs for preventing and / or treating calcified aortic valve diseases. The invention reveals for the first time that H-151 can inhibit the increase of the expression level of osteogenic differentiation markers ALP and RUNX2 in aortic valve interstitial cells induced by an osteogenic culture medium in an in-vitro experiment, and inhibit osteogenic differentiation and calcium salt deposition of the aortic valve interstitial cells; in addition, aortic valve thickening, fibrosis and calcium salt deposition of mice induced by an aortic valve injury model are inhibited in vivo. Based on the biological effect, the application of H-151 in developing the medicine for treating the calcified aortic valve disease is provided for the first time, and a new technical path and a new medicine choice are provided for preventing and treating the calcified aortic valve disease.

The invention relates to the technical field of genetic engineering, in particular to application of miR-145-3p as a target spot in preparation of products for regulating and controlling proliferation of goat testicular interstitial cells. According to the invention, Inhibitor and Mimics sequences taking the miR-145-3p gene as a target spot are constructed, and it is proposed for the first time that overexpression of the miR-145-3p gene can significantly inhibit proliferation of goat testicular interstitial cells, and inhibition of the miR-145-3p gene can significantly promote proliferation of goat testicular interstitial cells. The invention has important significance for improving the development of the goat testis, and provides technical support for researching and developing related products for regulating and controlling the proliferation of the goat testis interstitial cells by taking the miR-145-3p gene as a target spot.

The invention belongs to the technical field of reproductive biology, and particularly provides a method for separating and culturing testicular perichondrial muscle-like cells of an adult mouse. The method comprises the following steps: removing interstitial cells from testis tissues of an adult mouse, and digesting the testis tissues by pancreatin and DNA enzyme to obtain a testis single-cell suspension; and culturing by adopting a new isolated culture medium until the culture dish is full of cells, and carrying out cell passage, cell cryopreservation and resuscitation and cell identification by adopting passage culture mediums with different concentrations. According to the method for separating and culturing the mouse peridermoid cells, the cell separation degree is far higher than that in the prior art, operation is easy, time is saved, the technical blank that the mouse peridermoid cells are difficult to separate and culture is filled, and the method is suitable for large-scale popularization and application. And convenience is provided for research on interaction of the mouse testicular peritubular muscle-like cells with other testicular somatic cells and germ cells.

This invention provides the application of costunolide in the preparation of a drug for preventing posterior capsule opacification. Costunolide effectively reduces posterior capsule opacification after extracapsular lens extraction (ECLE) and exhibits significant anti-inflammatory and anti-fibrotic effects in both in vitro and in vivo models. Mechanistic studies have identified matrix metalloproteinase 8 (MMP8) as a key downstream effector of costunolide, confirming that costunolide inhibits MMP8 expression, thereby blocking the transformation of lens epithelial cells (LECs) into mesenchymal cells and subsequent fibrotic processes. This lays a solid foundation for developing targeted therapies for posterior cataract, a common surgical complication.

The application discloses a method for synchronously marking germ cells and interstitial cells in the testis tissue of Paralichthys olivaceus, which comprises the following steps: cloning MIR17HG-a (long non-coding RNA) of Paralichthys olivaceus by using a probe primer, obtaining a target plasmid after plasmid extraction, carrying out double enzyme digestion and purification to obtain an enzyme-digested plasmid as a probe template, synthesizing Paralichthys olivaceus MIR17HG-a probe by using an SP6 / T7 RNA polymerase, preparing a tissue slice from the testis tissue of Paralichthys olivaceus, and carrying out fluorescent in situ hybridization on the tissue slice by using the Paralichthys olivaceus MIR17HG-a probe, so that the Paralichthys olivaceus MIR17HG-a probe can synchronously mark the germ cells and interstitial cells in the testis tissue of Paralichthys olivaceus. The method solves the defects of traditional marking technology, such as the need for combined marking or multiple step-by-step marking, and fills the blank of synchronous marking of germ cells and interstitial cells in the testis tissue of Paralichthys olivaceus.

The invention discloses a method for synchronously marking germ cells and interstitial cells in paralichthys olivaceus testis tissues, which comprises the following steps: cloning paralichthys olivaceus MIR17HG-a (long non-coding RNA) by using a probe primer, and extracting plasmids to obtain target plasmids; the method comprises the following steps of: synthesizing a paralichthys olivaceus MIR17HG-a probe through SP6 / T7 RNA polymerase, preparing paralichthys olivaceus testis tissues into tissue slices, and performing fluorescence in-situ hybridization on the tissue slices by using the paralichthys olivaceus MIR17HG-a probe, so that the paralichthys olivaceus MIR17HG-a probe can synchronously mark germ cells and interstitial cells in the paralichthys olivaceus testis tissues. The defect that a traditional marking technology needs combined marking or multi-time step-by-step marking is overcome, and the blank of synchronous marking of germ cells and interstitial cells in paralichthys olivaceus testis tissue at present is filled.

The application belongs to the technical field of medicine, and particularly relates to a use of a flavonoid compound in aortic valve disease or cardiovascular aging. The flavonoid compound shown in formula I is found to be capable of inhibiting the osteogenic differentiation of valve interstitial cells for the first time. In animal implementation, the flavonoid compound can significantly reduce the peak flow rate and peak pressure difference of the aortic valve of a calcified aortic valve mouse, and has a significant effect of relieving aortic valve calcification. Therefore, the flavonoid compound has a good application prospect in the preparation of a drug for relieving aortic valve disease, relieving cardiovascular aging and other related cardiovascular diseases.

The invention relates to the technical field of probiotics, in particular to a lactic acid bacteria mixture for preventing and delaying heart valve calcification and application of the lactic acid bacteria mixture, and the lactic acid bacteria mixture comprises a saliva combined lactobacillus BR202 strain, a cheese paracasei BR176 strain, a bifidobacterium animalis subsp. Lactis BR621 strain and a plant lactobacillus PQQ-1 strain. According to the invention, human valvular interstitial cells are induced to generate osteogenic differentiation, so as to simulate pathological changes in calcified aortic valve diseases for evaluation, and the results of calcium salt deposition of the human valvular interstitial cells and osteogenic differentiation experiments of the human valvular interstitial cells prove that the human valvular interstitial cells can be used for simulating the pathological changes in the calcified aortic valve diseases. The lactic acid bacteria mixture can effectively delay calcium salt deposition of human valvular interstitial cells and osteogenic differentiation of the human valvular interstitial cells, so that the lactic acid bacteria mixture has the physiological activity function of preventing and delaying cardiac valve calcification, and can be used for preparing medicines or food compositions for preventing and delaying cardiac valve calcification.

The application belongs to the technical field of traditional Chinese medicine, and discloses application of matrine in preparation of a medicine for treating endometriosis and a medicine composition. The matrine used in the application can inhibit proliferation and promote apoptosis of ectopic stromal cells of endometriosis, and can also significantly inhibit metastasis and recurrence of the ectopic stromal cells, and can be widely applied in preparation of medicines for treating endometriosis, and has important clinical value.

The present application relates to a kind of drug based on PARM1 regulation treatment calcified aortic valve disease and its application.The present application first finds that PARM1 is significantly increased in the aortic valve of calcified aortic valve disease (CAVD) patient, and plays a key role in the osteogenic differentiation process of valve interstitial cells (VICs), and the expression level of PARM1 is knocked down can inhibit the osteogenic differentiation of VICs and extracellular calcium salt deposition, reduce aortic valve calcification, and its mechanism of action involves MAPK signal pathway.The present application provides a new target and treatment idea for the treatment of CAVD, and can be applied to related drug research and development and treatment method development.

The invention belongs to the technical field of organic synthetic drugs, and particularly relates to a cyclic pyrimidine derivative, a pharmaceutical composition and a preparation method and application of the cyclic pyrimidine derivative. A series of cyclic pyrimidine derivatives are synthesized, and the cyclic pyrimidine derivatives have good sGC agonist activity and can be used as sGC agonists. In-vivo and in-vitro experiments prove that the compound prepared by the invention obviously inhibits osteogenic differentiation of valvular interstitial cells, optimizes in-vivo pharmacokinetic characteristics, obviously reduces aortic valve peak flow velocity and peak pressure difference of a calcified aortic valve mouse, and has a good application prospect. The compound has the effect of relieving arterial valve calcification equivalent to or better than that of positive drugs (Vericiguat and Riciguat) with high administration dosage, and has a good application prospect in the aspect of preparing drugs for treating or relieving aortic valve diseases and other related cardiovascular diseases.

Aortic valve calcification is a condition in which calcium deposits form on the aortic valve in the heart. These deposits can cause narrowing at the opening of the aortic valve. This narrowing can become severe enough to reduce blood flow through the aortic valve—a condition called aortic valve stenosis. The inventors have shown that retinoic acid decreases calcification and osteoblast-like phenotype in valvular interstitial cells (VICs). More particularly, RARα activation reduces calcification and osteoblast-like phenotype in VIC. On the contrary, ALDH1A1 inhibition increases calcification and osteoblast-like phenotype in VIC. Thus the results prompt to consider that use or retinoic acid receptor (RAR) agonists would be suitable for the reversing, preventing or delaying calcification of the aortic valve.

The invention discloses an ovarian endometriosis glandular epithelial organ and interstitial cell co-culture model and a construction method thereof. The construction method comprises the following steps: S1, constructing an ovarian endometriosis cyst glandular epithelial organ; s2, constructing a 3D culture body of the ovarian endometriosis cyst interstitial cells; and S3, digesting the glandular epithelium organ, mixing the glandular epithelium organ with the interstitial cells in proportion, and embedding the glandular epithelium organ in matrigel for three-dimensional co-culture. According to the invention, a patient-derived ovarian endometriosis glandular epithelial organ and interstitial cell co-culture system is established for the first time, the model and a primary focus are highly homologous in tissue morphology and biomarker expression, and the bionic degree is high; it is clear that the number of glandular epithelial organs is the largest when the ratio of epithelial cell clusters to interstitial cells is 1: 2, the vitality of the glandular epithelial organs in a group with the ratio of 1: 2 to 1: 4 is remarkably improved, and the technical bottlenecks that an existing co-culture model is fuzzy in proportion, and the cell viability is difficult to maintain are solved.

This invention provides a method for isolating and identifying interstitial cells from Bactrian camels, belonging to the field of cell isolation technology. A mixture of 0.08–0.12% collagenase IV solution and 0.23–0.27% trypsin-EDTA at a volume ratio of 1:2 is used to digest Bactrian camel testicular tissue blocks. The mixture is then purified by hypotonic treatment to remove excess germ cells, differential adhesion purification to remove a large number of supporting cells, and Percoll density gradient centrifugation to remove a small number of supporting cells. The suspension, obtained from a 34%–60% Percoll gradient, is transferred to a new culture flask to obtain interstitial cells with a purity ≥95%. Identification is performed using morphological observation, immunofluorescence staining, and secretory function testing. The interstitial cells isolated from Bactrian camels using this invention can be used for research on the reproductive performance of Bactrian camels, laying the foundation for understanding the reproductive performance of Bactrian camels.

The application provides a combined drug for improving embryo implantation efficiency of RIF patients and a screening method, and belongs to the technical field of embryo implantation. In order to solve the problem of how to screen a general drug combination on the basis of a large heterogeneous RIF population, the application locks 1119 kinds of drugs that may have a therapeutic effect in a large range through a six-step screening method combined with advanced RNA sequencing technology, and then further screens the drugs by using a highly simulated endometrial epithelial organoid and stromal cell model, tests the influence of the 1119 kinds of drugs on the activity of the endometrial epithelial organoid and stromal cell, and finally screens 7 kinds of effective drugs which can form a broad-spectrum drug with significant therapeutic effect on RIF in a combined form. The 7 kinds of effective drugs screened by the application are icotinib, fumaric acid propofol tenofovir tablets, clopidogrel, tizacat, osimertinib, venetoclax and rebastinib.

The application discloses application of anucleated mesenchymal stem cells in preparation of drugs for preventing or treating calcified aortic valve diseases, and aims at the defects of aggravation of osteogenic differentiation, lung retention and poor targeting that may occur when mesenchymal stem cells are used to treat calcified aortic valve diseases, finds that the anucleated mesenchymal stem cells lose the osteogenic differentiation ability due to the absence of cell nuclei, and meanwhile, retain the functional organelles, metabolic activity, targeted migration ability, protein translation and paracrine function, can play an anti-CAVD role by inhibiting local inflammation of the valve, blocking osteogenic differentiation of valve interstitial cells and reducing calcium salt deposition, and the application further provides a preparation method of the anucleated mesenchymal stem cells and a corresponding pharmaceutical composition, the anucleated mesenchymal stem cells can target migration to a calcified aortic valve lesion after intravenous infusion, have no risk of osteogenic differentiation, are high in safety, provide a brand-new non-surgical treatment method for CAVD, and have excellent clinical conversion prospects.

The invention disclosed herein generally relates to methods and systems for converting stem cells into specific tissue(s) or organ(s) through directed differentiation. In particular, the invention disclosed herein relates to methods and systems for promoting human intestinal tissue (e.g., human intestinal organoid tissue) comprising epithelium, stroma, neurons, endothelial cells, and organized smooth muscle, and interstitial cells of Cajal (ICCs).

This invention belongs to the field of biomedical technology and relates to a pharmaceutical composition for alleviating stress-induced cardiac disease. The invention provides a pharmaceutical composition for alleviating stress-induced cardiac disease, comprising oxalic acid, coenzyme Q, and an NLRP3 inhibitor. This invention verifies that the pharmaceutical composition can significantly inhibit human valvular interstitial cell calcification and exhibits excellent synergistic therapeutic effects compared to a single NLRP3 inhibitor.

The invention provides a combined medicine for improving the embryo implantation efficiency of RIF patients and a screening method, and belongs to the technical field of embryo implantation. In order to solve the problem of how to screen general drug combinations on the basis of a huge heterogeneity RIF group, 1119 drugs which possibly have treatment effects are locked in a large range through a six-step screening method in combination with an advanced RNA (Ribonucleic Acid) sequencing technology; the method comprises the following steps: selecting 1119 types of medicines, then further utilizing a highly simulated endometrial epithelium organ and interstitial cell model to screen medicines, testing the influence of the 1119 types of medicines on the activity of the endometrial epithelium organ and interstitial cell, and finally screening 7 types of effective medicines to form a broad-spectrum medicine with a remarkable curative effect on RIF through a combination form. The seven effective drugs screened by the invention are respectively icotinib, a propofol fumarate tenofovir tablet, clopidogrel, tizacarbox, osimertinib, Vinetogram and ribotinib.

The invention disclosed herein generally relates to methods and systems for converting stem cells into specific tissue(s) or organ(s) through directed differentiation. In particular, the invention disclosed herein relates to methods and systems for promoting human intestinal tissue (e.g., human intestinal organoid tissue) comprising epithelium, stroma, neurons, endothelial cells, and organized smooth muscle, and interstitial cells of Cajal (ICCs).

The invention provides an application of costus lactone in preparation of a medicine for preventing posterior capsular opacity. The costuslactone can be used for effectively relieving posterior capsular opacity after ECLE (extracellular lens extraction), and shows remarkable anti-inflammatory and anti-fibrosis effects in both in-vitro and in-vivo models. Mechanism research determines that matrix metalloproteinase 8 (MMP8) is a key downstream effector factor of costus lactone, and confirms that costus lactone inhibits MMP8 expression so as to block conversion from lens epithelial cells (LECs) to interstitial cells and a subsequent fibrosis process, and lays a solid foundation for developing a targeted therapy for a common operative complication of posterior cataract.